Market Place
Sourcing Support
Mylan`s Generics Glucagon Receives Approval in US
12 Dec 2024 //
FDA
Mylan Pharma`s Biologic Semglee Receives Suppl Approval in US
25 Nov 2024 //
FDA
UK Watchdog Fines Viatris $1.9M Over Rule Breach In Theramex Probe
22 Nov 2024 //
REUTERS
Viatris fined in Morocco over merger notification, sources say
21 Nov 2024 //
REUTERS
Mylan`s Generics Sugammadex Receives Tentative Approval in US
20 Nov 2024 //
FDA
Safecor Health Acquires Viatris` US Unit-Dose Packaging Business
18 Nov 2024 //
PR NEWSWIRE
Viatris Reports Q3 Financial Results for 2024
07 Nov 2024 //
PR NEWSWIRE
Viatris Announces Q32024 Dividend
05 Nov 2024 //
PR NEWSWIRE
Viatris To Participate In UBS And Jefferies Healthcare Conferences
29 Oct 2024 //
PR NEWSWIRE
Viatris Named to Forbes` World`s Top Companies for Women 2024 List
29 Oct 2024 //
PR NEWSWIRE
Viatris Announces Licenses Sotagliflozin Outside U.S. And Europe
16 Oct 2024 //
PR NEWSWIRE
Lexicon Announces Licensing Agreement With Viatris For Sotagliflozin
16 Oct 2024 //
GLOBENEWSWIRE
Viatris lays out $25M to tackle marketing of Lexicon`s Inpefa
15 Oct 2024 //
FIERCE PHARMA
Viatris Reports Positive Results From Phase 3 Study In Japan
09 Oct 2024 //
PR NEWSWIRE
Viatris Named To Forbes` Annual List Of World`s Best Employers
08 Oct 2024 //
PR NEWSWIRE
Novo settles with Mylan over potential Ozempic generic
07 Oct 2024 //
FIERCE PHARMA
Gilead inks licensing deals to boost lenacapivir access
02 Oct 2024 //
FIERCE PHARMA
Viatris Announces the Pricing Terms of Maximum Tender Offer
18 Sep 2024 //
PR NEWSWIRE
Viatris Announces Early Tender Results And Increase In Pending Tender Offer
17 Sep 2024 //
PR NEWSWIRE
Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024
16 Sep 2024 //
PR NEWSWIRE
Viatris Announces Pricing Terms Of Any And All Cash Tender Offers
10 Sep 2024 //
PR NEWSWIRE
Viatris Announces Expiration, Results Of Any And All Cash Offers
10 Sep 2024 //
PR NEWSWIRE
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
04 Sep 2024 //
PR NEWSWIRE
Viatris Presents Late Breaking Abstract On Cenerimod At APLAR Congress
23 Aug 2024 //
PR NEWSWIRE
Viagra-maker Viatris beats Q2 estimates on branded and generic drug demand
08 Aug 2024 //
REUTERS
Viatris Reports Second Quarter Financial Results for 2024
08 Aug 2024 //
PR NEWSWIRE
Viatris Announces Second Quarter 2024 Dividend
06 Aug 2024 //
PR NEWSWIRE
Novartis, Viatris face new lawsuit over `HeLa` cell misuse claims
06 Aug 2024 //
REUTERS
Enforcement Report - Week of July 24, 2024
24 Jul 2024 //
FDA
Viatris closes divestitures of OTC business
08 Jul 2024 //
INDIAPHARMAPOST
Calliditas’ partner Viatris for phase III clinical trial with Nefecon in Japan
05 Jul 2024 //
PHARMABIZ
Viatris Completes All Announced Divestitures With OTC Business Sale Closure
05 Jul 2024 //
PR NEWSWIRE
Department of Justice No Longer Considers Mylan Subject Of Antitrust
02 Jul 2024 //
PR NEWSWIRE
Mylan Pharms Generic Aripiprazole Receives Tentative Approval in US
27 Jun 2024 //
FDA
Viatris Named to TIME`s World`s Most Sustainable Companies 2024 List
25 Jun 2024 //
PR NEWSWIRE
Kotak Alt funds Matrix founder`s buyout of Viatris API business
11 Jun 2024 //
ECONOMICTIMES
Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
07 Jun 2024 //
PR NEWSWIRE
Viatris: Attending Goldman Sachs Global Healthcare Conference
04 Jun 2024 //
PR NEWSWIRE
Viatris Appoints Rogerio Vivaldi Coelho, M.D., to Board of Directors
03 Jun 2024 //
PR NEWSWIRE
Viatris to Participate in the Jeffries Global Healthcare Conference
31 May 2024 //
PR NEWSWIRE
Viatris Publishes 2023 Sustainability Report On Sustainable Access
21 May 2024 //
PR NEWSWIRE
Mylan`s Generic Deferasirox Receives Approval in the U.S.
17 May 2024 //
FDA
Viatris Strong Q1 2024, Reaffirms 2024 Guidance Ranges
09 May 2024 //
PR NEWSWIRE
Mylan`s Generic Deferasirox Receives Approval in the U.S.
03 May 2024 //
FDA
Viatris to Participate in the BofA Securities 2024 Health Care Conference
02 May 2024 //
PR NEWSWIRE
Viatris Expands Wellbeing With Mental Health Resource Unmind
01 May 2024 //
PR NEWSWIRE
Viatris ranked 2024 LinkedIn top companies list in India for nurturing talent
29 Apr 2024 //
PHARMABIZ
Viatris, eyeing a return to growth, taps Moderna, Amgen alum as Cco
16 Apr 2024 //
FIERCE PHARMA
Viatris Appoints Corinne Le Goff As Chief Commercial Officer
15 Apr 2024 //
PR NEWSWIRE
Viatris launches RYZUMVl 0.75% in US
02 Apr 2024 //
INDIANPHARMAPOST
Teva, Viatris win new chance to challenge J&J schizophrenia drug patent
02 Apr 2024 //
REUTERS
Viatris Announces the Launch of RYZUMVl™ 0.75% in the United States
01 Apr 2024 //
PR NEWSWIRE
Viatris Focusing on its Collabo with Idorsia, Ph 3 Selatogrel and Cenerimod
27 Mar 2024 //
PR NEWSWIRE
Mylan`s Generic Darunavir Receives Tentative Approval in the U.S.
26 Mar 2024 //
FDA
Idorsia and Viatris close the transaction for the global R&D collaboration
18 Mar 2024 //
GLOBENEWSWIRE
FDA Rejects Viatris, Mapi’s Long-Acting Multiple Sclerosis Injection
12 Mar 2024 //
BIOSPACE
Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results
28 Feb 2024 //
PR NEWSWIRE
Viatris forecasts strong 2024 sales on higher demand for branded drugs
28 Feb 2024 //
REUTERS
Idorsia and Viatris enter into a global research and development collaboration
27 Feb 2024 //
GLOBENEWSWIRE
Mylan`s Generic Lopinavir and Ritonavir Receives Approval in the U.S.
07 Feb 2024 //
FDA
